Andrea Bonetto

IGF-1 is downregulated in experimental cancer cachexia.

New strategies to overcome cancer cachexia: from molecular mechanisms to the 'Parallel Pathway'.

The cytosolic sialidase Neu2 is degraded by autophagy during myoblast atrophy.

Are antioxidants useful for treating skeletal muscle atrophy?

Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?

Therapeutic potential of proteasome inhibition in Duchenne and Becker muscular dystrophies.

Glutamine prevents myostatin hyperexpression and protein hypercatabolism induced in C2C12 myotubes by tumor necrosis factor-α.

β-hydroxy-β-methylbutyrate (HMB) attenuates muscle and body weight loss in experimental cancer cachexia.

Changes in myostatin signaling in non-weight-losing cancer patients.

STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia.

Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia.

JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia.

MuRF-1 and p-GSK3β expression in muscle atrophy of cirrhosis.

Early changes of muscle insulin-like growth factor-1 and myostatin gene expression in gastric cancer patients.

Assessment of muscle mass and strength in mice.

STAT3 in the systemic inflammation of cancer cachexia.

Effect of the specific proteasome inhibitor bortezomib on cancer-related muscle wasting.

Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.

Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways.